Investigational drug · Phase 3
BERLIM 25
Also called: 20 ASSOCIATION
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Dyslipidemia Associated With Type II Diabetes Mellitus.
Phase 3Last checked: Nov 19, 2026Latest source record: Dec 8, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "BERLIM 25"
First trial start
2023
Dec 1, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
- EMS1
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BERLIM 25", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dyslipidemia Associated With Type II Diabetes Mellitus
Approved drugs for the same conditions: Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "BERLIM 25" as an intervention, largest first.
- Efficacy and Safety of Berlim 25/10 Association in the Treatment of Type II Diabetes Mellitus and DyslipidemiaPivotal-lookingStatus unknown
EMSIndustry
NCT04603508 · 240 participants (planned) · Start Mar 2023 · Primary completion Apr 2025
Drug: BERLIM 25/10 association; EMPAGLIFLOZIN and 1 more · For: Type 2 Diabetes Mellitus; Dyslipidemia
- Efficacy and Safety of Berlim 25/20 Association in the Treatment of Type II Diabetes Mellitus and Dyslipidemia.Pivotal-lookingRecruiting
EMSIndustry
NCT04602754 · 228 participants (planned) · Start Dec 1, 2023 · Primary completion May 2026
Drug: BERLIM 25/20 ASSOCIATION; EMPAGLIFLOZIN and 1 more · For: Dyslipidemia Associated With Type II Diabetes Mellitus
Sites: Campinas, Brazil
Newest research
PubMed records naming it or its code names, newest first.
- Time to Diagnosis and Treatment for Ovarian Cancer and Associations with Outcomes: A Systematic Review.
Bergin RJ, O'Sullivan D, Dixon-Suen S, et al. · J Womens Health (Larchmt) 2024
- Teaching and Evaluating the Virtual Physical Exam in Telemedicine.
Yarnall R, Monkman H, Akel M, et al. · Stud Health Technol Inform 2024
- TractGeoNet: A geometric deep learning framework for pointwise analysis of tract microstructure to predict language assessment performance.
Chen Y, Zekelman LR, Zhang C, et al. · Med Image Anal 2024
- Post-traumatic stress disorder as a predictor for incident hypertension: a 3-year retrospective cohort study.
Mendlowicz V, Garcia-Rosa ML, Gekker M, et al. · Psychol Med 2023
- Risk of Non-infectious Uveitis with Metformin Therapy in a Large Healthcare Claims Database.
Sobrin L, Yu Y, Han S, et al. · Ocul Immunol Inflamm 2022
- White matter association tracts underlying language and theory of mind: An investigation of 809 brains from the Human Connectome Project.
Zekelman LR, Zhang F, Makris N, et al. · Neuroimage 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.